Please visit answersincme.com/860/102653681-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus Berdeja, MD; and Saad Z. Usmani, MD, MBA, FACP, FASCO. In this activity, experts in multiple myeloma (MM) discuss how BCMA bispecific antibody (BsAb)–anti-CD38 monoclonal antibody combinations fit into the treatment paradigm for patients with relapsed/refractory MM. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BCMA BsAbs in combination with anti-CD38 antibodies in the treatment of patients with RRMM; Review the clinical implications of the latest efficacy and safety data for BCMA BsAbs in combination with anti-CD38 antibodies in patients with RRMM; Outline potential considerations for integrating BCMA BsAbs in combination with anti-CD38 antibodies, as they become available, into the treatment of patients with RRMM, in the community setting; and Apply practical tools for optimizing the use of BCMA BsAbs in the community setting.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related